Acorda Therapeutics, Inc. (ACOR) rated Mkt Underperform with price target $5 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Underperform Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 10/12/2009, when the stock price was $17.89.
Since then, Acorda Therapeutics, Inc. has gained 91.28% as of 06/17/2013's recent price of $34.22. If you would have followed this Rodman & Renshaw's recommendation on ACOR, you would have lost 47.72% of your investment in 1344 days.
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.